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Introduction
BC is a heterogeneous disease comprises different 
subtypes classified according to the expression of ER, PR, 
HER-2, and Ki-67 [Caswell and Swanton, 2017; Osako et 
al., 2017). Most cases are with Hormone-receptor positive 
tumors and have a relatively better clinical outcome 
(Dunnwald et al., 2007). By contrast, triple negative BC 
is an aggressive and heterogeneous disease with poor 
prognosis, which increases the need for other treatment 
modalities like immunotherapy (Davis et al., 2014). 
Several studies revealed the role of the immune system 
in cancer; including cancer immunoediting process which 
eliminates immunogenic tumor cells by the host immune 
system (Criscitiello and Curigliano, 2015). 
Cancer, as a genetic disease, results in accumulation 
of somatic mutations in the DNA of the affected cells. 
Some somatic mutations can give rise to neoantigens 
that are recognized and targeted by the immune system. 
Not only immunogenic neoantigens affect the ability of 
T cells to identify and kill tumor cell, but mutations in 
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immunologically relevant genes can also do, for example; 
mutations in JAK1, JAK2, B2M, and STK11genes 
(Skoulidis et al., 2018). 
TMB represents one of the most rapidly emerging 
biomarkers for cancer immunotherapy and many ongoing 
clinical trials registered in ClinicalTrials.gov are using it 
as a stratification biomarker (Chan et al., 2018). Currently, 
immune checkpoint blockade (ICB) can offer a significant 
clinical benefit to cancer patients; most notably melanoma 
(Hodi et al., 2010), non-small-cell lung cancer (NSCLC) 
(Borghaei wt al., 2015), urothelial cancer (Rosenberg et 
al., 2016) and renal cell carcinoma (Motzer et al., 2018). 
There are limited reports about TMB in BC. However, 
TMB is higher in ER-negative tumors when compared 
to ER-positive tumors, and it may be of a relatively 
high value in TNBC patients (Luen et al., 2016). The 
reference for TMB quantification is Whole Exome 
Sequencing (WES). However, it was reported that gene 
panels that target 1.5 to 3 Mb of the genome space are 
precise for TMB estimation (Buchhalter et al., 2019). 
In our previously published data, we reported the most 
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identified somatic mutations in the first Egyptian cohort to 
sequence a multiple-gene panel of cancer related genes on 
BC patients (Nassar et al., 2020). Here in, using the same 
panel, we aims to identify the TMB value in Egyptian BC 
patients and to find the best model to predict it, based on 
the expression of ER, PR, HER-2, and Ki-67. Thereby, 
predicting patients’ prognosis and response to treatment. 
Materials and Methods
Patients
Fifty-eight female Egyptian BC patients were enrolled 
in this study from the Egyptian National Cancer Institute. 
They were all naive to treatment and their classification 
was according to age, histological grade, lymph node 
involvement, menopause status, ER, PR, HER-2, and 
Ki-67 expression. All the patient’s clinicopathological 
features were obtained from clinical records. All the tissue 
samples were preserved at −80 °C until being extracted.
Ethical approval 
Fifty-eight tissue samples were collected at surgery 
and after the agreement of all patients with a written 
informed consent. This study was approved by the 
Institutional Review Board of NCI, Cairo University, 
Egypt which conducted in accordance with ICH-GCP 
guidelines (IRB number: IRB00004025). 
Targeted DNA library preparation and sequencing with 
the ion torrent proton system
The genomic DNA was isolated using QIAamp® 
DNA Mini Kit (Cat. No. 51304, Qiagen, Germany) 
following manufacturer’s instructions. DNA was then 
measured using Qubit® 3.0 Fluorometer (Cat. No, 
Q33216, Thermo fisher Scientific Inc, USA). The library 
was constructed using the Ion AmpliSeq Comprehensive 
Cancer panels (Ion AmpliSeq CCP, Life Technologies, 
Cat. No. 4477685) and the Ion AmpliSeqTM Library Kit 
2.0 (Cat. No.4480441). Libraries were quantified using 
the Ion Library Quantitation Kit (Life Technologies, Cat. 
no. 4468802) and sequenced with the ion torrent proton 
system.
Detection of somatic mutations and calculation of TMB 
value
The high-quality reads of each NGS run were aligned 
to the human reference genome (version hg19) using the 
Torrent Suite. TSVC Torrent Suite module was used to call 
the somatic variants with hotspots. Then, the variants with 
all available public population information were annotated 
using ANNOVAR (Yang and Wang, 2015) package. The 
Catalogue of Somatic Mutations in Cancer COSMIC (Tate 
et al., 2019) and CIViC (Griffith et al., 2017) databases 
were used to annotate variants in cancer. TMB was defined 
as the number of somatic, non-silent, base substitution, and 
indel mutations per mega base of the examined genome.
Statistical analysis
All data were analyzed with SPSS (version 22.0). 
According to the quartile method, method divides dataset 
into three points (a lower quartile, median, and upper 
quartile) to form four groups, the TMB distribution 
was divided into 4 groups as follow: A (0.00-0.625), B 
(0.626-1.25), C (1.251-2.50), and D (>2.50). Forest plot 
for univariate logistic regression analysis was used for 
TMB distribution according to ER, PR, HER-2, & Ki-67 
expression. 
Machine learning classification models for prediction of 
TMB in the studied BC patients 
Different classification machine learning algorithms; 
logistic regression, kernel support vector machine (SVM), 
K-nearest neighbor (KNN), Decision tree and Forrest 
decision, were initially evaluated to select the optimal 
classification model for prediction of TMB level according 
to patient’s receptor status. Grid search was used to find 
the best hyperparameters for the highest accuracy across 
an extent of model specific parameters. First, the dataset 
was split into 75% training set and 25% test set. The 
models were built in 6-fold cross validation (CV) on the 
training set to evaluate the model on different validation 
sets.  The model performance was evaluated as accuracy, 
Receiver Operating Characteristic (ROC) curve with area 
under the curve score (AUC) and Matthews Correlation 
Coefficient. The evaluation metric generally regarded as 
a balanced measure that represents, in a single value, the 
confusion matrix of the classifier even if the classes are 
of very different sizes. The MCC value is between -1 and 
+1 where +1 indicates the perfect prediction, 0 an average 




The median age of the studied patients was 54.6 (range 
from 29 to 77). The majority of the presented patients 
were with ER-positive (65.5%), PR-positive (55.2%), 
HER2-negative (70.7%), and Ki-67 positive (56.9%). 
Also, 41 patients out of 58 (70.7%) were postmenopausal; 
48 patients out of 58 (82.7%) had positive lymph node 
involvement and only 9 patients out 58 (15.5%) were 
classified as triple negative (Table 1). 
Distribution of TMB in our studied sample set
TMB value was calculated as the number of somatic, 
base substitution, non-silent, and indel mutations per 
coding area of the genomic sequence examines (~1.6 
Mb). The TMB distribution in the 58 studied Egyptian 
BC patients was as follow: 19 cases in group A (33%), 12 
cases in group B (21%), 14 cases in group C (24%), and 
13 cases in group D (22%). The TMB value was between 
0.00 and 8.12. The median value of TMB in the total BC 
cohort was 1.25 mutations/ Mb. The top quartile value and 
maximum value of TMB were 2.5 mutations/Mb and 8.12 
mutations/Mb, respectively (Figure 1).
TMB for different categories of the studied markers
Univariate logistic regression analysis of a training 
set with 10-fold cross validation showed that ER 
positive expression was significantly associated 
with TMB ≤ 1.25 (ER positive vs ER-negative, OR 
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=0.12, 95% CI: 0.025–0.52, p= 0.005). Also, PR positive 
expression was significantly associated with TMB ≤1.25 
(PR positive versus PR negative, OR = 0.17, 95% CI= 
0.04-0.67, p= 0.01). On the other hand, Ki-67 expression 
positive was significantly associated with TMB >1.25 than 
those who were Ki-67 expression negative (Ki-67 positive 
versus Ki-67 negative, OR = 6.56, 95% CI= 1.67-20, p= 
0.008). While, TMB >1.25 was significantly distributed 
in TN patients than non-TN patients (OR=9.69, 95% CI= 
1.05-26, p=0.045). However, no significant differences 
were observed between HER2 positive and HER2 negative 
group (OR = 3.69, 95% CI: 0.79-17.1, p =0.09) (Figure 2).
The distribution of ER/PR/HER2/Ki-67 in the four TMB 
groups
We used the quartile method to measure the spread 
of values above and below the mean by dividing the 
distribution into four groups as it divides the dataset into 
three points; a lower quartile, median, and upper quartile. 
Table 2 shows TMB distribution in relation to patients’ 
demographic and clinical data. We found that ER and PR 
positivity associated significantly with lower TMB quartile 
while, higher TMB quartile was significantly observed 
in patients with positive Ki-67 expression and TNBC. 
Significant differences were found between positive and 
negative ER expression in TMB Group 1 (27.5% and 
5.2%, respectively, p=0.0029) and TMB group 2 (18.9% 
and 1.7%, respectively, p=0.0038). Ki-67 index was 
significantly overexpressed in the top TMB quartile group 
4 (20.1%) compared to the other groups (8.6%, p<0.001). 
The TNBC subtype associated significantly with the higher 
TMB group 4 compared to the other groups (p=0.025). For 
the distribution of PR, we observed that PR positivity was 
significantly higher in lower TMB group compared to the 
other groups (p= 0.017). A significant difference between 
HER2 positivity and negativity in the lower quartiles TMB 
group 1 (6.9% and 25.9%, respectively, p= 0.011) and 
group 2 (3.4% and 17.2%, p=0.02).
Patients characteristics Total (N =58) Percentage (%)
Age(years)
     <55 27 46.6
     ≥55 31 53.4
Menopausal status
     Premenopausal 17 29.3
     Postmenopausal 41 70.7
LN involvement 
     0 10 17.2
     1 to 3 17 29.3
     >3 31 53.4
Grade
     1 4 6.9
     2 45 77.5
     3 9 15.6
ER
     Negative 20 34.5
     Positive 38 65.5
PR
     Negative 26 44.6
     Positive 32 55.2
HER2
     Negative 41 70.7
     Positive 17 29.3
Ki67
     <14% 25 43.1
     ≥14% 33 56.9
Triple negative
     Non-TN 49 84.5
     TN 9 15.5
Table 1. Clinical Features of the Studied 58 Egyptian BC 
Patients
Figure 1. Distribution of TMB in 58 BC Tissue Samples. Density of TMB Represents the Percentage of BC Samples at 
Various TMB Levels. (Abbreviations: TMB, tumor mutation burden; muts/Mb, mutations/megabase; Max, maximum)
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Machine learning classification models for prediction of 
TMB in the studied BC patients 
Different classification machine learning algorithms; 
logistic regression, kernel support vector machine (SVM), 
K-nearest neighbor (KNN), Decision tree and Forrest 
decision, were initially evaluated to select the optimal 
classification model to predict TMB value according to 
patient’s characteristics (Figure 3). 
The performance of the machine learning models with 
the best hyperparameters optimization was shown in Table 
3. First, the most relevant features (ER, PR, HER2, Ki-67 
and TN) were selected for prediction of TMB category 
using the Select KBest class of the scikit-learn library. 
The prediction of TMB was based on its categorization 
into 2 classes high TMB (>1.25 mutations/bp) and low 
TMB (≤1.25 mutations/bp). The KNN and decision tree 
were the best predictive model for prediction of TMB 
class based on the selected patient’s features having 
the highest accuracy (74.4 ± 9.76 and 74.11 ± 5.99, 
respectively) and AUC (0.81 ± 0.15 and 0.81 ± 0.25) 















     Negative 20 3 (15.8) 1 (8.3) 8 (57.1) 8 (61.5) 0.003*
     Positive 38 16 (84.2) 11 (91.7) 6 (42.9) 5 (38.5)
PR
     Negative 26 4 (21.1) 4 (33.3) 9 (64.3) 9 (69.2) 0.017*
     Positive 32 15 (78.9) 18 (66.7) 5 (35.7) 4 (30.8)
HER2
     Negative 41 15  (78.9) 10 (83.3) 7 (50.0) 9 (69.2) 0.22
     Positive 17 4 (21.1) 2 (16.7) 7 (50.0) 4 (30.8)
Triple negative
     Non-TN 49 18 (94.7) 12 (100.0) 11 (78.6) 8 (61.5) 0.025*
     TN 9 1 (5.3) 0 (0.0) 3 (21.4) 5 (38.5)
Ki67
     <14% 25 14 (73.7) 6 (50.0) 4 (28.6) 1 (7.7) 0.0015*
     ≥14% 33 5 (26.3) 6 (50.0) 10 (71.4) 12 (92.3)
Grade
     1 4 0 (0.0) 2 (16.7) 0 (0.0) 2 (15.4)
     2 45 17 (89.5) 6 (50.0) 12 (85.7) 10 (76.9) 0.12
     3 9 2 (10.5) 4 (33.3) 2 (14.3) 1 (7.7)
LN 
     0 10 4 (21.1) 2 (16.7) 3 (21.4) 1 (7.7)
     1 to 3 17 4 (21.1) 3 (25.0) 3 (21.4) 7 (53.8) 0.52
     >3 31 11 (57.9) 7 (58.3) 8 (57.2) 5 (38.5)
Menopausal status
     Premenopausal 17 6 (31.5) 5 (41.7) 3 (21.4) 3 (23.1) 0.66
     Postmenopausal 41 13 (68.5) 7 (58.3) 11 (78.6) 10 (76.9)
Age
     <55 27 9 (47.4) 7 (58.3) 6 (42.9_ 5 (38.5) 0.78
     ≥55 31 10 (52.6) 5 (41.7) 8 (57.1) 8 (61.5)
Table 2. Quartile Group Distribution of TMB According to Clinicopathological Characteristics
Model Accuracy ± SD (%) Mean AUC Hyperparameters
Logistic Regression 72.22 ± 6.4 0.83 ± 0.18 penalty = L2 and C= 1.0
Kernel SVM 71.73 ± 12.04 0.76 ± 0.17 C = 1, kernel is Gaussian, and gamma is 0.01.
K Nearest neighbor (KNN) 74.4 ± 9.76 0.81 ± 0.15 Algorithm: auto, leaf_size: 1, n_jobs: -1, n_neighbors: 5
Decision tree 74.11 ± 5.99 0.81 ± 0.25 Criterion: gini ,  max_depth: 4 ,  Number Of Components: 3
Random forest tree 71.73 ± 12.04 0.73 ± 0.17 max_depth: 5, min_samples_leaf: 1, n_estimators: 25
Table 3. Performance Models Used for Prediction of TMB Level According to Patient’s Receptor Status
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(Figure 4). These were followed by logistic regression 
with an accuracy of 72.22 ± 6.4 and AUC of 0.83 ± 0.18 
(Figure 4).  The adjusted McFadden’s Pseudo R-Squared 
approach was used to evaluate the logistic regression 
model for prediction whether TMB ≤ median (group 1 
and 2) or TMB > median (group 3 and 4). The adjusted 
Pseudo-R2 was 0.329 (P<0.001). The optimized logistic 
regression model was TMB = -27.5 -1.82 ER – 0.73 PR 
+ 0.826 HER2 + 2.08 Ki-67 (Figure 4). 
Discussion 
BC is the most common malignancy among women 
worldwide. BC was classified based on the presence of 
the ER, PR, HER-2, and Ki-67, the routinely available 
markers in each BC specimen (Osako et al., 2017). The 
process of eliminating highly immunogenic tumor cells 
by somatic evolution is known as cancer immunoediting 
that uses the host immune system to protect it from 
tumor development. The increased burden of somatic 
mutations has been associated with the immunogenicity 
of BC (Criscitiello and Curigliano, 2015). Thus, we are in 
indeed need to assess the TMB to help in immunotherapy 
decision making.
In this study, the measured TMB was calculated 
by Ion AmpliSeq Comprehensive Cancer Panel using 
NGS technology. TMB value was between 0 and 8.13/
Mb and majority of cases was distributed in the TMB 
group A (0.00-0.625) indicating the lower mutation 
rate in our studied patients. BC tumors have low 
Figure 2. Forest Plot for Univariate Logistic Regression Analysis of TMB Distribution. (Abbreviations: OR, odds 
ratio; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2)
Figure 3. Pipeline Used to Develop Machine Learning Classification Model for Prediction of TMB in BC Cases. 
(Abbreviation: SVM, support vector machine; KNN, K-nearest neighbor) 
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Figure 4. Classification Models Used for Prediction of TMB Value 
immunogenicity to escape the immune recognition (Ross 
and Gay, 2017). Typically, BC harbors mutational loads 
averaging one mutation per Mb (Kandoth et al., 2013). 
Moreover, immune-suppressive factors are released in 
the tumor microenvironment which leads to difficult 
antigen presentation and results in low immune response 
(Mittendorf et al., 2007). Furthermore, cancer-associated 
immunogens are less common in BC (Disis et al., 1994). 
However, somatic mutations frequency or TMB is 
associated with the immunogenicity of BC (Criscitiello 
and Curigliano, 2015). Recently, TMB has emerged as 
a predictive marker to immunotherapy response across 
different tumors, including melanoma, lung cancer, and 
BC (Goodman et al., 2017). However, the heterogeneity 
of TMB among BC subtypes is not well characterized.
Here in, we described the TMB differences between 
hormone receptor-positive and hormone receptor-negative 
Egyptian BC patients. Our findings showed that hormone 
receptor-positive was associated with TMB ≤1.25 (ER 
positive vs ER-negative, OR =0.35, 95% CI: 0.04–2.98, 
p= 0.001) (PR positive versus PR negative, OR = 0.17, 
95% CI= 0.02-0.44, p= 0.002), which comes in agreement 
with a recent study by Xu et al., (2019). 
Matching with Xu et al., (2018), we revealed that higher 
TMB was distributed in Ki-67 expression positive patients 
than those with Ki-67 expression negative. However, they 
reported that patients with HER-2 expression positive 
was significantly associated with TMB (HER-2 positive 
vs HER-2 negative, OR =34.81, 95% CI: 3.711–821.689, 
P=0.0065) which was not the situation in our study (Xu et 
al., 2018). In the current study, no significant differences 
of TMB were observed between HER2 positive and HER2 
negative groups (OR = 2.47, 95% CI: 0.64-9.54, p =0.19). 
Based on the current findings, we suggest that hormone 
receptor-negative BC or Ki-67 expression positive BC 
exhibits relatively elevated TMB and immunotherapeutic 
options are recommended.
Many ongoing immunotherapeutic approaches 
in BC are used to increase the quality or quantity of 
effector immune cells, and eliminate cancer-induced 
immunosuppression. For example, therapeutic 
administration of monoclonal antibodies to treat metastatic 
TNBC, including CTLA-4, PD-1 or Treg cells (Adams 
et al., 2019). In the present study, our findings suggested 
that hormone receptor positive and Ki-67 expression 
positive Egyptian BC patients showed high immunogenic 
activity when compared to hormone receptor negative 
and Ki-67 expression negative patients. Thus, they may 
be considered for immune checkpoint inhibition and 
suggesting the use of TMB as a biomarker for cancer 
immunotherapy.
Not only immunogenic neoantigens, but also mutations 
in immunologically relevant genes, can affect the ability 
of T cells to identify and kill tumor cell, for example; 
mutations in JAK1, JAK2, B2M, and STK11genes 
(Skoulidis et al., 2018). We previously reported the 
presence of certain somatic mutations in JAK2, JAK3, and 
STK11 genes in a cohort of Egyptian BC patients (Nassar 
et al., 2020). Hence, we suggest conducting targeted 
sequencing of immunologically relevant genes in addition 
to TMB to be used as biomarkers to enhance predicting 
the patients’ prognosis and response to immunotherapy.
In conclusion, we showed that hormone receptor 
negative and Ki-67 expression positive Egyptian BC 
patients exhibit TMB value >1.25. We also showed that 
TMB value can be predicted based on the expression level 
of ER, PR, HER-2, and Ki-67 and the optimized logistic 
regression model was TMB = -27.5 -1.82 ER – 0.73 PR 
+ 0.826 HER2 + 2.08 Ki-67. 
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Recommendation
We recommend increasing sample size to avoid false 
positive results. Also, following up the patients until 
recurrence or metastasis is crucial to find the correlation 
between TMB and the survival data.
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